11 completed, 4 unknown, 2 active not recruiting, 2 recruiting. 22 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 11, Unknown 4, Active not recruiting 2, Recruiting 2, Terminated 2, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Febrile Neutropenia: new trials by email Literature Review of Febrile Neutropenia trials Research Report on Febrile Neutropenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy ceftazidime, ciprofloxacin, Standard-of-Care Antibiotic Strategy - Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | Zealand University Hospital | 150 | 2027-03-01 | 2026-09-25 |
| Phase II Study of QLC2519 in Pediatric Solid Tumor Participants Albipagrastim alf - Pediatric Malignant Solid Tumor, Febrile Neutropenia (FN) | Phase 2 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 18 | 2026-06-26 | 2026-07-24 |
| Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents - Myelosuppression, Thoracic Neoplasms | Phase 2 | Recruiting | Affiliated Hospital of Nantong University | 30 | 2025-08-01 | 2025-12-11 |
| A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors Efgbemalenograstim alfa - Non Small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 99 | 2023-12-31 | 2023-11-22 |
| Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy Day 7 regimen, Day 3 regimen - Breast Cancer | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 160 | 2021-07-13 | 2023-02-23 |
| Pentaglobin in CRE and PA Neutropenic Infections Pentaglobin - Septic Shock | Phase 2 | Active not recruiting | Gruppo Italiano Trapianto di Midollo Osseo | 120 | 2019-12-06 | 2025-01-06 |
| Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial Anakinra, Placebos - Multiple Myeloma | Phase 2 | Completed | Radboud University Medical Center | 88 | 2019-11-04 | 2024-11-18 |
| Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer EC-18 - Febrile Neutropenia | Phase 1 / Phase 2 | Completed | Enzychem Lifesciences Corporation | 28 | 2017-10-30 | 2026-11-04 |
| Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia Magnesium Oxide Supplement - Febrile Neutropenia | Phase 2 | Unknown | Universidad Nacional Autonoma de Mexico | 214 | 2017-10-19 | 2018-03-05 |
| Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT Anakinra - Multiple Myeloma | Phase 2 | Completed | Radboud University Medical Center | 9 | 2017-08-21 | 2024-11-18 |
| Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant Piperacillin-tazobactam, cefepime - Intestinal Microbiome, Febrile Neutropenia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 347 | 2017-02-10 | 2026-03-04 |
| Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer CAZ-AVI, Vancomycin, Linezolid - Neoplasms, Febrile Neutropenia | Phase 2 | Terminated | Forest Laboratories | 2 | 2016-05-17 | 2017-07-21 |
| Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) Filgrastim, Peg-filgrastim - Breast Cancer, Neutropenia | Phase 2 | Terminated | Asan Medical Center | 22 | 2016-02-01 | 2020-07-31 |
| Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML G-CSF - Leukemia, Myeloid, Acute | Phase 2 / Phase 3 | Unknown | Seoul St. Mary's Hospital | 56 | 2015-03-01 | 2015-04-28 |
| Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle, YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle - Non Small Cell Lung Cancer, Breast Cancer | Phase 2 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 80 | 2013-12-01 | 2018-07-17 |
| Study of Danggui Buxue Decoction in Preventing Neutropenia DBD, Epirubicin, Cyclophosphamide - Grade 3/4 Neutropenia, Febrile Neutropenia | Phase 2 | Completed | Shanghai Jiao Tong University School of Medicine | 50 | 2013-10-01 | 2015-12-30 |
| A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg) - Advanced Metastatic (Stage IV) Colorectal Cancer | Phase 1 / Phase 2 | Completed | Egetis Therapeutics AB (publ) | 186 | 2012-09-01 | 2018-07-06 |
| Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer empegfilrastim, filgrastim - Chemotherapy-induced Neutropenia | Phase 2 | Completed | Biocad | 60 | 2012-05-01 | 2016-12-05 |
| Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Micafungin sodium, Itraconazole - Febrile Neutropenia, Hematological Diseases | Phase 2 | Completed | Yonsei University | 153 | 2011-06-01 | 2014-12-08 |
| A Phase II Study Comparing Pegylated rhG-CSF(HHPG-19K) and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy Pegylated rhG-CSF 100μg/kg, Pegylated rhG-CSF:150 μg/kg, rhG-CSF 5 μg/kg/day - Breast Cancer, Neutropenia | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 182 | 2011-02-01 | 2014-04-22 |
Showing 20 of 22. Sign in to see all of them.
Neutropenia (9) · Breast Neoplasms (6) · Multiple Myeloma (3) · Carcinoma, Non-Small-Cell Lung (2) · Mucositis (2) · Neoplasms (2) · Colorectal Neoplasms (1) · Fever (1) · Hematologic Diseases (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Pseudomonas Infections (1) · Shock, Septic (1) · Thoracic Neoplasms (1)
Agranulocytosis (22) · Cytopenia (22) · Hemic and Lymphatic Diseases (22) · Leukocyte Disorders (22) · Leukopenia (22) · Hematologic Diseases (21) · Neoplasms (13) · Neutropenia (13) · Neoplasms by Site (9) · Breast Diseases (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Neoplasms by Histologic Type (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3)
Filgrastim (3) · pegylated granulocyte colony-stimulating factor (3) · Cefepime (2) · Interleukin 1 Receptor Antagonist Protein (2) · Piperacillin, Tazobactam Drug Combination (2) · Anidulafungin (1) · Ceftazidime (1) · Ciprofloxacin (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Granulocyte Colony-Stimulating Factor (1) · Itraconazole (1) · Linezolid (1) · Meropenem (1)
Radboud University Medical Center (2) · Affiliated Hospital of Nantong University (1) · Asan Medical Center (1) · Biocad (1) · Egetis Therapeutics AB (publ) (1) · Enzychem Lifesciences Corporation (1) · Forest Laboratories (1) · Gruppo Italiano Trapianto di Midollo Osseo (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · Pfizer (1) · Qilu Pharmaceutical Co., Ltd. (1) · S&D Pharma SK s.r.o. (1) · Seoul St. Mary's Hospital (1) · Shanghai Jiao Tong University School of Medicine (1)
China (7) · South Korea (4) · United States (4) · Denmark (2) · Netherlands (2) · Bulgaria (1) · Georgia (1) · Germany (1) · Italy (1) · Mexico (1) · Portugal (1) · Russia (1) · Serbia (1) · Slovakia (1) · Sweden (1)
Nicole Blijlevens, MD PhD (2) · Bart Biemond, MD PhD (1) · David Melnick, M.D. (1) · Fabio Ciceri (1) · Gerwin Huls, MD PhD (1) · Jae-Ho Yoon (1) · Kunwei Shen, Dr (1) · Marie Bengtson (1) · Martijn Bakker, MD (1) · Michal Mego, MD, PhD (1) · Miguel A Palomo, PhD (1) · Pavel Bician, MD (1) · Roman A. Ivanov, MD, PhD (1) · Sung-Bae Kim, MD, PhD (1)
PMID 29140155, PMID 33030582, PMID 33225965, PMID 35546555, PMID 39533204
2018 (1)